New research has found that stem cells derived from human cord blood could be an effective alternative in repairing heart attacks.
At least 20 million people survive heart attacks and strokes every year, according to World Health Organisation estimates, but many have poor life expectancy and require continual costly clinical care. The use of patient’s own stem cells may repair heart attacks, although their benefit may be limited due to scarce availability and ageing. The researchers have found heart muscle-like cells grown using stem cells from human umbilical cord blood could help repair heart muscle cells damaged by a heart
The King Abdulaziz Medical City in Riyadh is getting ready to open a stem cell bank harvested from the umbilical cord. The procedure will be done in laboratories and specially equipped rooms to draw the cells from umbilical cord blood and separate them using a special device.
Then they will be stored in labs for a period from 15 to 20 years after examining them and making sure they are free of contagious and genetic diseases. In addition, a team will be prepared for coordinating, marketing and research within this field.
Researchers have discovered that umbilical cord stem cells, found in the blood of the umbilical cord, and able to differentiate into various types of tissue, represent a valid treatment alternative for leukemia patients that cannot find a compatible donor for a bone marrow transplant. American hematologists meeting in San Francisco for the 50th American Society of Hematology (ASH) Congress are now focusing their research on these types of stem cells to fight blood borne tumors.
An American study has recently called attention to the possible applications of umbilical cord stem cells for leukemia treatments. For years,
CordLife, Asia Pacific’s largest network of stem cell banks, on Wednesday launched the most advanced umbilical cord banking technology in the country. The technology has the ability to isolate two cell types that help in hastening the healing process of diabetic foot ulcers.
The patented technology allows access epithelial stem cells that can rejuvenate skin and mucus membranes for treating non-healing wounds as is seen in diabetic ulcer patients, said Steven Fang, group CEO, CordLife. With over 4 crore people in the country diagnosed with diabetes and 1 in every 6 estimated to have an ulcer during the lifetime, CordLife
Leukemia, the most common form of childhood cancer, affects the blood-forming cells in the bone marrow. It is often treated with stem cell transplants that replace the patient’s bone marrow cells with stem cells donated by a healthy individual. Successful transplant depends on finding a donor who is a close genetic match to the patient. That’s a particular challenge for patients from racial and ethnic minority groups, who may die while waiting for a matching donor.
But a mostly-untapped source of genetically diverse stem cells is right under our noses: Blood left in the umbilical cord after a baby is